C4 Therapeutics Achieves Milestone with Delivery to Biogen
C4 Therapeutics Marks a Significant Collaboration Milestone
C4 Therapeutics, Inc. (C4T) has reached an important milestone in its journey as a clinical-stage biopharmaceutical company. Recently, the company successfully delivered its second development candidate to Biogen, culminating in an impressive $8 million milestone payment. This achievement underscores C4T's commitment to advancing targeted protein degradation science.
Delivery of the Innovative Degrader Candidate
Announcing this achievement, Andrew Hirsch, the president and CEO of C4 Therapeutics, expressed excitement over delivering a highly effective, brain-penetrant, orally bioavailable BiDAC™ degrader candidate. This new development is particularly significant as it aligns with Biogen's mission to discover and develop innovative therapies aimed at enhancing patient outcomes.
Collaboration and Achievements
C4 Therapeutics and Biogen have established a collaborative framework since 2018, wherein C4T offers expertise in targeted protein degradation. In this integral partnership, Biogen brings its extensive scientific knowledge and drug development capabilities to the table. It's noteworthy that C4T is not only hitting milestones but also fostering meaningful advancements in medicine with such collaborations.
Leveraging TORPEDO™ Platform
The achievements of C4 Therapeutics can be largely attributed to its proprietary TORPEDO™ platform. This innovative technology has demonstrated remarkable potential in designing and optimizing small-molecule medicines aimed at tackling challenging diseases. Since its founding in 2015, C4T has successfully discovered and advanced multiple development candidates, including the two significant candidates delivered to Biogen, which highlights the effectiveness of the platform.
Future Prospects in Oncology
C4 Therapeutics is making strides in targeted oncology programs and focuses on developing therapies that utilize the body's natural protein recycling system. These degrader medicines are designed to degrade disease-causing proteins swiftly, potentially overcoming drug resistance and addressing previously undruggable targets. Their approach promises significant improvements in patient care and outcomes.
About C4 Therapeutics
C4 Therapeutics is at the forefront of biopharmaceutical innovation, driven by the mission to deliver advanced therapies that transform patients' lives. The company's unwavering determination and scientific expertise in targeted protein degradation continue to yield positive results in its clinical studies.
Contact Information
For more inquiries regarding C4 Therapeutics, interested parties may reach out to:
Investor Relations:
Courtney Solberg
Senior Manager
Email: CSolberg@c4therapeutics.com
Media:
Loraine Spreen
Senior Director, Corporate Communications & Patient Advocacy
Email: LSpreen@c4therapeutics.com
Frequently Asked Questions
What milestone did C4 Therapeutics achieve?
C4 Therapeutics delivered its second development candidate to Biogen, leading to an $8 million milestone payment.
What technology does C4 Therapeutics use?
The company's innovative TORPEDO™ platform is utilized for developing small-molecule medicines targeting difficult diseases.
Who is responsible for clinical development of the delivered candidates?
Biogen is responsible for all future clinical development and commercialization of the candidates delivered under the collaboration.
How many development candidates has C4 delivered to Biogen?
C4 Therapeutics has successfully delivered two development candidates to Biogen under their collaboration.
What is the focus of C4 Therapeutics?
C4 Therapeutics focuses on advancing targeted protein degradation science to create transformative medications for patients.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.